Background
Method
Clinical data
Patient population
REA treatment
REA procedure
Histopathology and immunohistochemical assay
Histology and immunostaining
Assessment of immunohistochemical assay
Statistics
Results
The effect on DUB of the hormone-treated control and the REA-treated groups
Endometrial histopathology before and 6 to 7 months after REA
Histopathological types | Control groups n(%) | Statistics | ||
---|---|---|---|---|
Before treatment | After treatment |
χ
2
|
P
| |
Fibrous connective tissue and granulation tissue | 0 (0.0%) | 0 (0.0%) | - | - |
Some endometrial glands and granulation tissue | 0 (0.0%) | 0 (0.0%) | - | - |
Proliferative endometrium | 8 (25.0%) | 15 (46.9%) | 3.326 | >0.05 |
Simple hyperplasia | 14 (43.8%) | 12 (37.5%) | 0.259 | >0.05 |
Complex hyperplasia | 10 (31.2%) | 5 (15.6%) | 2.177 | >0.05 |
Histopathological types | REA group n(%) | Statistics | ||
---|---|---|---|---|
Before treatment | After treatment |
χ
2
|
P
| |
Fibrous connective tissue and granulation tissue | 0 (0.0%) | 20 (30.3%) | 23.030 | <0.01 |
Some endometrial glands and granulation tissue | 0 (0.0%) | 27 (40.9%) | 32.832 | <0.01 |
Proliferative endometrium | 16 (24.2%) | 13 (19.7%) | 0.461 | >0.05 |
Simple hyperplasia | 30 (45.5% | 4 (6.1%) | 25.611 | <0.01 |
Complex hyperplasia | 20 (30.3%) | 2 (3.0%) | 17.220 | <0.01 |
Expression of survivin, ER, and PR expression before and 6 to 7 months after treatment in the control group
Pathology before treatment |
n
| Before treatment (mean ± SD) | After treatment (mean ± SD) | ||||
---|---|---|---|---|---|---|---|
Survivin scores | ER (%) | PR (%) | Survivin scores | ER (%) | PR (%) | ||
Proliferative endometrium | 8 | 5.5 ± 1.2 | 53.3 ± 18.1 | 40.6 ± 27.3 | 5.7 ± 1.8 | 55.6 ± 30.1 | 51.8 ± 37.0 |
Simple hyperplasia | 14 | 6.1 ± 1.8 | 58.1 ± 16.3 | 44.7 ± 262 | 5.9 ± 1.6 | 57.6 ± 34.3 | 50.7 ± 30.1 |
Complex hyperplasia | 10 | 8.5 ± 2.0 | 86.2 ± 36.2 | 85.3 ± 21.5 | 6.7 ± 2.3 | 82.7 ± 32.1 | 77.1 ± 36.4 |
Expression of survivin, ER, and PR before and 6 to 7 months after treatment in REA treatment group
Pathology before treatment |
n
| Before treatment (mean ± SD) | After treatment (mean ± SD) | ||||
---|---|---|---|---|---|---|---|
Survivin scores | ER (%) | PR (%) | Survivin scores | ER (%) | PR (%) | ||
Proliferative endometrium | 16 | 5.7 ± 1.7 | 53.3 ± 18.3 | 45.9 ± 22.3 | 2.5 ± 1.7a | 23.8 ± 10.4a | 11.3 ± 7.5a |
Simple hyperplasia | 30 | 7.2 ± 1.7 | 51.4 ± 15.7 | 54.2 ± 25.7 | 1.8 ± 0.9a | 18.9 ± 14.4a | 26.9 ± 11.3a |
Complex hyperplasia | 20 | 8.1 ± 2.3 | 79.9 ± 20.4 | 86.7 ± 31.6 | 2.9 ± 0.3a | 18.3 ± 12.1a | 21.4 ± 6.8a |